http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kim, Dohun,Kim, Hong Kwan,Kim, Seok-Hyung,Lee, Ho Yun,Cho, Jong Ho,Choi, Yong Soo,Kim, Kwhanmien,Kim, Jhingook,Zo, Jae Ill,Shim, Young Mog AME Publishing Company 2018 Journal of thoracic disease Vol.10 No.1
<P>Conclusions: Histologic subtype according to the IASLC/ATS/ERS classification and TDR both correlated with pathologic invasiveness and predicted survival in patients with lung adenocarcinoma with GGO.</P>
Hong, Suk,Li , Yan,Eom , Joo Beom,Choi , Yongdoo AME Publishing Company 2018 Quantitative imaging in medicine and surgery Vol.8 No.8
<P>Conclusions: This nanogel system may have potential utility for selective NIR fluorescence imaging and combined chemo/radio therapy of proliferating macrophage cells in atherosclerotic regions, allowing for reduction of systemic toxicity.</P>
The mutational signatures and molecular alterations of bladder cancer
AME Publishing Company 2017 Translational cancer research Vol.6 No.-
<P>All cancers are transformed from normal cells as a result of somatic alterations in the genomes. During the last few years, many research groups, including the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA), have conducted large-scale cancer genome studies worldwide. These efforts identified millions of somatic mutations accumulated in cancer cells, including point mutations, copy number variations and chromosomal rearrangements, as well as gene expression profiles and genome-wide DNA methylation patterns. These datasets accelerated our understanding of many biological processes operative in cancers. Genomes of bladder cancer, one of the most common cancers worldwide, were recently analyzed by several groups, which provide a comprehensive landscape of molecular alterations. This review article discusses the patterns of somatic mutations, mutational signatures, frequently altered genes and molecular pathways in bladder cancers.</P>
Emerging targeted therapies in advanced bladder cancer
Go, Yong Hyu,Yoo, Juno,Noh, Jung Hyun,Kim, Chan AME Publishing Company 2017 Translational cancer research Vol.6 No.-
<P>The prognosis of advanced urothelial bladder cancer (UBC) is dismal despite conventional platinum-based chemotherapy and, as such, new therapeutic agents are urgently needed. Recently, many novel molecular-targeted agents inhibiting immune checkpoints, VEGF/R, FGF/R, or EGF/R are being developed in clinical trials. Among them, immune checkpoint inhibitors (ICI) targeting the PD-1/PDL1 pathway have shown the most promising outcomes with durable clinical response and favorable safety profile. Agents targeting VEGF/R, FGF/R, or EGF/R pathways are still being investigated and are not providing clear clinical benefit yet. An appropriate selection of fit patients may be necessary for further clinical development of these agents. While we are still in the beginning of targeted therapy for advanced UBC, recent breakthroughs in ICI treatment and accumulating knowledge in molecular biology of UBC will provide a new horizon in the future treatment of UBC.</P>
Suh, Yoon Seok,Jeong, Kyung-Chae,Lee, Sang-Jin,Seo, Ho Kyung AME Publishing Company 2017 Translational cancer research Vol.6 No.-
<P>The prognosis and treatment of bladder cancer have hardly improved in the last 20 years, with the exception of immunotherapy using a PD-1/PD-L1 blocker, which was approved by the United States Food and Drug Administration in 2016. Hence, bladder cancer remains a debilitating and often fatal disease, and among one of the costliest cancers to treat. Preclinical models that are more representative of human cancer are urgently needed to improve our understanding of bladder cancer progression, as well as advance its diagnosis and treatment. Patient-derived xenografts (PDXs), involving the transfer of tumor fragments from individual patients into immunocompromised animals such as severe combined immunodeficient or nude mice, have been developed and utilized as a preclinical model of bladder cancer. PDX models recapitulating clinical behavior, including the drug response of several cancers, have demonstrated high predictive capacity to test standard chemotherapy regimens and to identify tumor types that might benefit from new treatments in clinical trials. However, current PDX models have limitations to their translation into current clinical trials including PD-1/PD-L1-related trials and personalized medicine. This review focuses on the advantages and disadvantages of PDX models in drug development, their application in bladder cancer, and future directions of PDX models.</P>
Lee, Jaehee,Lim, Jae Kwang,Kim, Eun Jin,Lee, Deok Heon,Kim, Yu Kyung,Yoo, Seung Soo,Lee, Shin Yup,Cha, Seung Ick,Park, Jae Yong,Kim, Chang Ho AME Publishing Company 2018 Journal of thoracic disease Vol.10 No.5
<P>Conclusions: The present study suggests that treatment completion, the cause of death, and risk factors for TB-related deaths may be different according to age groups in adult patients with miliary TB.</P>
CO2 during single incisional thoracoscopic bleb resection with two-lung ventilation
Lee, Dong Kyu,Kim, Heezoo,Kim , Hyun Koo,Chung , Dong Ik,Han , Kook Nam,Choi , Young Ho AME Publishing Company 2018 Journal of thoracic disease Vol.10 No.8
<P>Conclusions: SITS with CO2 insufflation during ST-TLV did not produce a superior surgical field except at the beginning of surgery. CO2 insufflation required more time and resulted in higher mean PaCO2 and peak airway pressure.</P>